A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
- PMID: 20371346
- PMCID: PMC2851638
- DOI: 10.1016/j.cell.2010.02.027
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
Abstract
Accumulating evidence implicates heterogeneity within cancer cell populations in the response to stressful exposures, including drug treatments. While modeling the acute response to various anticancer agents in drug-sensitive human tumor cell lines, we consistently detected a small subpopulation of reversibly "drug-tolerant" cells. These cells demonstrate >100-fold reduced drug sensitivity and maintain viability via engagement of IGF-1 receptor signaling and an altered chromatin state that requires the histone demethylase RBP2/KDM5A/Jarid1A. This drug-tolerant phenotype is transiently acquired and relinquished at low frequency by individual cells within the population, implicating the dynamic regulation of phenotypic heterogeneity in drug tolerance. The drug-tolerant subpopulation can be selectively ablated by treatment with IGF-1 receptor inhibitors or chromatin-modifying agents, potentially yielding a therapeutic opportunity. Together, these findings suggest that cancer cell populations employ a dynamic survival strategy in which individual cells transiently assume a reversibly drug-tolerant state to protect the population from eradication by potentially lethal exposures.
Copyright 2010 Elsevier Inc. All rights reserved.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2851638/bin/nihms182868f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2851638/bin/nihms182868f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2851638/bin/nihms182868f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2851638/bin/nihms182868f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2851638/bin/nihms182868f5.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2851638/bin/nihms182868f6.gif)
![Figure 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2851638/bin/nihms182868f7.gif)
Comment in
-
Drugging drug resistance.Cell. 2010 Apr 2;141(1):18-20. doi: 10.1016/j.cell.2010.03.020. Cell. 2010. PMID: 20371339
Similar articles
-
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade.Nat Commun. 2021 Jul 14;12(1):4319. doi: 10.1038/s41467-021-24618-3. Nat Commun. 2021. PMID: 34262032 Free PMC article.
-
Dissecting contributions of catalytic and reader domains in regulation of histone demethylation.Methods Enzymol. 2020;639:217-236. doi: 10.1016/bs.mie.2020.04.015. Epub 2020 Apr 30. Methods Enzymol. 2020. PMID: 32475402 Free PMC article.
-
JARID1 Histone Demethylases: Emerging Targets in Cancer.Trends Cancer. 2017 Oct;3(10):713-725. doi: 10.1016/j.trecan.2017.08.004. Epub 2017 Sep 12. Trends Cancer. 2017. PMID: 28958389 Free PMC article. Review.
-
The KDM5 family of histone demethylases as targets in oncology drug discovery.Epigenomics. 2014 Jun;6(3):277-86. doi: 10.2217/epi.14.14. Epigenomics. 2014. PMID: 25111482
-
Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease.Epigenomics. 2012 Apr;4(2):163-77. doi: 10.2217/epi.12.3. Epigenomics. 2012. PMID: 22449188 Free PMC article. Review.
Cited by
-
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia.Genome Biol. 2024 May 31;25(1):143. doi: 10.1186/s13059-024-03260-4. Genome Biol. 2024. PMID: 38822412 Free PMC article.
-
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers.NPJ Precis Oncol. 2024 May 31;8(1):124. doi: 10.1038/s41698-024-00615-9. NPJ Precis Oncol. 2024. PMID: 38822082 Free PMC article.
-
The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistance.J Exp Clin Cancer Res. 2024 May 30;43(1):151. doi: 10.1186/s13046-024-03078-9. J Exp Clin Cancer Res. 2024. PMID: 38812026 Free PMC article.
-
Advances in the molecular regulation mechanism of tumor dormancy and its therapeutic strategy.Discov Oncol. 2024 May 25;15(1):184. doi: 10.1007/s12672-024-01049-2. Discov Oncol. 2024. PMID: 38795254 Free PMC article. Review.
-
A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance.Oncogene. 2024 Jun;43(23):1727-1741. doi: 10.1038/s41388-024-03054-9. Epub 2024 May 8. Oncogene. 2024. PMID: 38719949 Free PMC article. Review.
References
-
- Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. Science. 2004;305:1622–1625. - PubMed
-
- Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784. - PubMed
-
- Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O’Connor M, Yao Y, Pachter J, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008;68:8322–8332. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous